Stay up to date with COEUS news and headlines

Stay up to date with COEUS news and headlines

FOR IMMEDIATE RELEASE

MEDIA CONTACT: Owen Murphy
215.680.0155
omurphy@coeusholdings.com

Mirador Global LP and e-Projection formally partner to Further Enhance the Global Reach and Depth of Services Offered by Both Companies

Philadelphia, PA, USA – May 20, 2022 – Mirador Global, LP and e-Projection K.K. speciality consultancies based in Philadelphia, PA, USA and Tokyo, Japan, respectively, today announced a partnership to develop expanded outreach to mutual markets. The partnership will allow both parties to promote businesses to geographies previously unreached, and to mutually share each party’s robust capabilities. Specifically, the partnership gives each company entrée into the other’s country affording both companies the opportunity to bring new business into Japan, the worlds’ 3rd largest market for pharmaceuticals.  Additionally, e-Projection will be able to deliver its insights and services to previously untapped markets by augmenting the needs of Mirador clients.

Mirador helps biopharmaceutical companies develop robust and integrated global commercialization strategies. The company brings extensive consulting expertise to global drug commercialization and market access efforts.

e-Projection is a Tokyo-based consulting firm that helps companies and institutions, namely in the pharmaceutical and biotechnology industries, enter the Japanese market with their products and technologies.

Through this partnership, e-Projection will be able to promote its business to North America and the EU, and Mirador will be able to do so to Japan. Both parties will engage in joint activities to serve their clients in a truly global context, including global research projects and global sales forecasting models.

“We are excited by this opportunity to partner with e-Projection Japan to gain access to their deep experience and expertise in this critical market, stated Lizzie Grosset, Vice President Global Access Strategy, Mirador Global LP. “The partnership enables Mirador us to provide truly global strategic consulting service to its clients. In turn, we look forward to collaborating with e-Projection’s talented team to support the generation of clear, robust US and EU insights-based strategies for their Japanese client base.”

“We have been impressed by the skills and capabilities of the experts at Mirador in the last few years and are thrilled to formalize our partnership with this great company,” said Tosh Nagate, CEO at e-Projection. “With this collaboration, we will develop global insights and strategies that are penetrating and actionable to our Japanese customer base and, at the same time, help the biotech community across the globe with cutting edge findings from the Japanese market.”

About e-Projection

e-Projection is a Tokyo-based consulting firm dedicated to global biotech, pharma, investors, and academic institutions who are interested in bringing their products/technologies to the Japanese market. e-Projection is a one-stop-shop consultancy which covers all the necessary factors for a non-Japanese biotech/pharmaceutical to plan to enter the Japanese market. To learn more about e-Projection, visit http://e-projection.com/

Hixson Was Recognized in the Transformational Leader Category

DEVON, PA – 5.17.22 [AF1] – COEUS Holdings and its subsidiaries, together a leading health outcomes, contracting, technology and commercial insights consulting firm, is pleased to announce that its President & CEO, Marc Hixson, has been named a recipient of a 2022 PM360 Elite 100 Award. PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, has named Hixson as one of the 2022 PM360 ELITE 100 in the Transformational Leader category. Now in its eighth year, the PM360 ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today. 

Since COEUS’ inception in 2009 there has been an emphasis on building service offerings and technologies to help drive the healthcare industry in a more sustainable and financially appropriate direction. Marc’s vision and clear understanding of where the healthcare industry and regulatory bodies are headed has catapulted COEUS and its now five integrated business units into double-digit revenue growth year-over-year for the last decade.

“It’s an honor to be named a Transformational Leader by PM360 for their ELITE 100 Awards,” stated Marc Hixson, President and CEO, COEUS Holdings. “Each year PM360 does a stellar job of recognizing industry leaders in a variety of categories so I’m in good company. I’m looking forward to attending the event and meeting the other recipients and the many people who are committed to advancing patient access to innovative, lifesaving therapies.”

The PM360 ELITE Awards were established in 2015 to recognize individuals and teams who have made a significant impact on the life sciences and healthcare industries throughout their careers. More than 500 submissions were received, and nominees were evaluated and selected by the PM360 editorial staff based on their accomplishments; testimonials from their bosses, clients, and colleagues; and supporting evidence that reflects the impact of their efforts. A total of 100 winners were selected across 20 categories, including Creative Directors, Data Miners, Digital Crusaders, Disrupters, Drug Researchers and Developers, Entrepreneurs, Environmental Champions, Launch Experts, Leaders of the Future, Marketing Teams, Master Educators, Mentors, Patient Advocates, Philanthropic Heroes, PR Gurus, Sales MVPs, Strategists, Talent Acquisition Leaders, Tech-know Geeks, and Transformational Leaders.

“Our industry accomplished great things during the pandemic to ensure people could be protected against COVID, treated for it, and still access all of the other medications they need, but this disruption to our world also revealed ways in which our industry could be even better,” says Anna Stashower, CEO and Publisher of PM360. “Many of this year’s winners sprang into action to improve areas the pandemic exposed as needing changes, including addressing health equity, social determinants of health, clinical research, patient access and affordability, and much more. That’s what makes them the most influential people our industry has to offer—their ability to push the industry forward to make healthcare better for all.”

The winners were profiled in PM360’s May 2022 issue. You can read their profiles online at https://www.pm360online.com/the-2022-pm360-elite-100.   

Additionally, the 2022 ELITE 100 will be celebrated at the annual ELITE Awards Event, which will be held at 230 FIFTH in New York City on July 13th starting at 7 PM EST. A special keynote address from Uber ELITE Winner Mikael Dolsten, MD, PhD, Chief Scientific Officer and President, Worldwide Research, Development, and Medical, Pfizer Inc., will kick off the celebration.

Tickets for the event can be purchased at https://www.pm360online.com/elitetickets.

#  #  #

About PM360

PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.


 [AF1]Owen, date correct?

This Appointment Will Further Expand the Company’s Thought Leadership and Continue to Support the Healthcare Industry’s Movement Towards Value-Based Care

September 21, 2021 – Devon, PA – COEUS Consulting Group, a wholly owned subsidiary of COEUS Holdings and together a leading health outcomes, contracting, technology and commercial insights consulting firm, today announced it has hired Matthew Paul as Senior Vice President, Value & Access. Mr. Paul joins the COEUS team after a successful career within senior leadership in the healthcare reinsurance industry most recently at Skyward Accident & Health, formerly known as Houston International Insurance Group (HIIG).

As Senior Vice President, Value & Access, Matt will be responsible for educating pharma/biotech clients on how the reinsurance market may impact their therapy’s utilization, developing actionable strategies on mitigating risk and building technology solutions that remove barriers to access. In addition, Matt will be responsible for building a new service line and solutions geared towards reinsurers themselves to better reduce their risk and exposure in the market.

“COEUS has worked long and hard to build its reputation as a leader in the market in tying health outcomes together with value-based care delivery in an effort to manage drug spend and ensure that appropriate patients receive the therapies they need,” said Marc Hixson, CEO of COEUS Holdings. “Matt’s reinsurance experience in a sector of the market that isn’t clearly understood by employers, manufacturers, and patients will bring tremendous value to all of our clients as they continue to innovate and pay for drugs.”

Prior to Joining COEUS, while at Skyward, Matt had oversight of the A&H Medical Stop Loss division where he worked closely with producers and internal regional underwriting teams to navigate best pricing and condition setting for their mutual clients. Over the past few years, the business model has changed from providing a rate driven product to being consultative, creative, and collaborative due to the emergence of high-cost drugs and therapies that are simply too expensive for the underlying plan to absorb.

“Over the years I have watched as innovative drugs and treatments have come to market while also watched as insurers and self-funded employers figure out how to pay for them. The market is now at a tipping point. In order to continue to see the innovation in drug development, we have to do a better job at figuring out innovative ways to show their value for the cost they carry,” said Mr. Paul, “without that value, innovation will cease, and many diseases will never see a cure. The COEUS team shares that same passion and drive and I look forward to helping be a part of that solution.”

About COEUS Consulting Group
Founded in 2009, COEUS Consulting Group is a boutique life sciences market access strategy consulting firm offering clients commercial support across the entire development spectrum. Our core focus is on delivering thoughtful insight and recommendations for our clients, and we accomplish that by utilizing a unique team of industry experts specific to each client’s needs in conjunction with a broad network of partners and advisors. The Market Access practice works with clients to develop their managed care and pricing and contracting strategy, market access insight generation, HEOR strategy and tactics, launch readiness, account management, operational support, patient access, distribution, and trade and advocacy/policy work. To learn more about COEUS and the company’s offerings, visit www.coeusconsultinggroup.com.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.
COEUS Media Contact:
Owen Murphy | 215.680.0155
owen@hyperclearcommunications.com

Acquisition Advances COEUS Solution’s Scalability and Capacity, Providing Clients a More
Robust Set of Offerings

September 21, 2021 – Devon, PA – As COEUS Holdings continues to drive its overall strategic growth plan of ensuring patients have appropriate access to innovative therapies when they need them, the access-focused firm has acquired Afore, a NJ-based customer-centric life sciences consulting firm that focuses on delivering commercial technology solutions and support.

The acquisition enables COEUS to augment and enhance its existing technology capabilities and, in many cases, provide a variety of new services to its client base. Among the services the combined entity will offer include commercial roadmap consulting, software integration services, data integration services, data warehousing and business intelligence solutions, training, and more.

“Today, pharmaceutical manufacturers spend a lot of time, money, and resources trying to understand, select, and implement the right systems, which requires a forward-thinking technology partner to make informed and forward-looking technology decisions,” said Marc Hixson, President & CEO of COEUS Holdings. “Afore’s team of experts specializes in providing clients with that evaluation, implementation and support services and has been independently ranked as the top technology partner by companies such as Veeva, TGaS Advisors and MediSpend. By incorporating Afore into the COEUS Solutions business, COEUS will strengthen its existing commercial technology enablement offerings related to information management, customer relationship management, and regulated content management and add a wealth of new consulting services.”

James Corbett, former pharmaceutical company senior executive and founder of Afore, will serve as
COEUS Solutions Chief Operations Officer. In this role, he will work to enhance the company’s go-to-market strategy, while ensuring that the team is structured appropriately, and client needs are being met.

“The team at Afore is excited to be joining the COEUS Solutions family during a time of exponential growth within the organization,” stated Corbett. “We look forward to contributing our knowledge and experience towards COEUS’ future as the synergies between the organizations–including client support, implementation services, and unique product offerings–will enable us to reach more clients and provide solutions leading to the optimal outcomes they need and expect.”

“The pace of innovation in healthcare requires cutting-edge technologies to optimize patient access to those products as they come to market,” said Mike Zubey, Chief Business Officer of COEUS Solutions. “This is another step in making COEUS Holdings an elite transformation partner for emerging biotech and large Pharma alike. In addition, Afore’s ranking as the top Veeva and Information Management partner to emerging biotech’s is directly in line with our overall strategy. With the technological insights of James and his team, COEUS Solutions has now significantly broadened its offering ensuring that clients will get where they need to go faster and in more scalable fashion.”

Corbett will work directly with Zubey to ensure that COEUS clients are well-informed on the various technology solutions available to them, and which can be best tailored to their specific needs and desired outcomes. Along with the rest of the COEUS leadership team, the two will work to continue to deliver technology and consulting solutions for their clients to ensure patients get access to the therapies they require and deserve.

About COEUS Holdings
The COEUS Holdings teams are singularly driven to optimize market access and commercialization infrastructure for pharmaceutical products. COEUS is a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. COEUS’ mission is to ensure patient access beyond the prescription. We focus on becoming your ally in navigating the healthcare universe. COEUS teams advance thought leadership, technology solutions, and communication initiatives to ensure your brands’ lifelong success. Together, we strive to redefine access solutions in the evolving domestic and global managed care markets. To learn more about COEUS and the company’s offerings, visit www.coeusholdings.com.

About COEUS Solutions
COEUS Solutions provides its clients IT strategy consulting, technology implementation, and integration services along with managed technology and functional services. This ensures that COEUS customers are properly prepared to commercialize and have technology and procedural solutions in place to safeguard success – not only at product launch, but in a sustainable fashion.

COEUS Media Contact:
Owen Murphy | 215.680.0155
owen@hyperclearcommunications.com

Services will enhance and further support COEUS’ commitment to bringing innovative therapies to market

November 5, 2020 – Devon, PA – COEUS Holdings, LLC and its subsidiaries, together a leading boutique life sciences consulting firm, announced today that it has officially launched COEMIRA, the access agency. Emerging after months in stealth mode, the agency is well positioned to assist clients with increasing awareness and access to lifesaving medications. The launch of COEMIRA continues to align to COEUS’ strategic mission to provide clients with additional service offerings and optimize efforts to show true value to all stakeholders in the healthcare ecosystem.

Created based on the feedback and requests from COEUS’ current clients, COEMIRA promises to be a unique agency focused on further optimizing strategies and tactics around launching novel therapies to market and activities that drive post-launch success. COEMIRA will integrate its offerings with the capabilities and subject matter expertise found in COEUS Consulting Group, MIRADOR Global, and COEUS HealthCare.

COEUS has named industry veteran Jodie McVan to the newly created role of vice president, agency services and operations, to continue to build and lead the overall management of COEMIRA. With nearly two decades of experience focused in the agency space, Jodie brings COEMIRA a unique convergence of industry experience, agency expertise, and operational excellence. “Having an expert like Jodie on board to build and run COEMIRA allows us to hit the ground running, bringing additional support to our clients right away,” said Marc Hixson, CEO of COEUS Holdings, “we have spent the last six months integrating the agency with our other subsidiaries and have created a seamless process that will only continue to add value to our clients and the lives of their patients.”

Jodie shared “I am continually impressed by the level of knowledge and talent we have under one roof. Our in-house experts have firsthand industry experience that provides real-world perspectives that truly impacts the effectiveness of our agency recommendations.”

To learn more about COEMIRA, the access agency, and how they can enhance your therapies’ presence with key stakeholders, please visit www.COEMIRA.com.

About COEMIRA
Founded in 2020, COEMIRA, the access agency, is a full-service content, creative, and digital agency providing ideation and execution for materials geared toward healthcare decision makers, providers, and patients. We provide the full continuum of strategic and tactical services for targeted market access and reimbursement communications. Powered by in-house expertise and market insights, we excel in identifying optimal solutions to reach the right audience with the right message at the right time.

COEMIRA understands that the evolving healthcare landscape requires agility, constant adaptation, and novel ways to effectively communicate with all stakeholders involved in the patient journey. Part of the COEUS family, COEMIRA brings nuanced expertise in clinical differentiation, access challenges, and patient services, to inform and optimize marketing efforts across stakeholders.

Our market access agency veterans know when to do things differently. We take pride in effective communication and efficient delivery, to help you maximize our client’s investment. For more information, visit www.COEMIRA.com.

About COEUS Holdings
Founded in 2020, COEUS Holdings, LLC and its subsidiaries form a boutique life sciences market access strategic and tactical consulting firm offering clients commercial support across the entire development spectrum. COEUS teams are singularly driven to optimize market access for pharmaceutical products. We are a multi-specialty, commercially aligned consultancy, offering a comprehensive suite of informed solutions for successful engagement with organized customers, providers, and patients. Leveraging years of collective real-world market expertise, we offer unique perspectives into clinical and business opportunities to support your brands’ position in the marketplace. For more information, please visit www.coeusholdings.com

Further Builds on the Company’s Commitment to Provide Executive-Level Expertise to all Clients in every Engagement

August 4, 2020 – Devon, PA – Coeus Consulting Group, a leading boutique life science consulting firm focused in market access, today announced it has hired Doug Brown as the Senior Vice President of Value and Access to help grow and manage the company’s enhanced market access offerings.

Brown brings more than 30 years of pharmacy management experience, the last 18 years working with Magellan Rx where his focus was on government markets, working to address strategies that help improve operational efficiency and stakeholder value in Medicaid. Before becoming Chief Strategy Officer, he served as Vice President of both Account Management and Value Based Solutions.

“All of Coeus welcomes Doug to the team, a true expert in Medicaid he will add critical value and insights to our internal team and clients,” said Marc Hixson, CEO of Coeus. “Also, with a final ruling on value-based contracting agreements and their effect on best price coming from CMS in the near future, his expertise will prove invaluable as we continue to innovate and support clients bringing their drugs to market.”

Further, Doug will provide Coeus and its clients subject matter expertise on federal and state government legislation that impacts state Medicaid programs supporting the foundation for an Outcomes Based Contracting program in Medicaid with the intent of pivoting the drug pricing discussion away from unit cost and toward reducing total cost of care. He will continue to be a resource for officials from CMS, NGA, MACPAC as well as legislative officials to help shape Medicaid policy to benefit State Medicaid programs and the beneficiaries they serve.

About Coeus Consulting Group
Founded in 2009, Coeus Consulting Group is a boutique life sciences market access strategy consulting firm offering clients commercial support across the entire development spectrum. Our core focus is on delivering thoughtful insight and recommendations for our clients, and we accomplish that by utilizing a unique team of industry experts specific to each client’s needs in conjunction with a broad network of partners and advisors. The Market Access practice works with clients to develop their managed care and pricing and contracting strategy, market access insight generation, HEOR strategy and tactics, launch readiness, account management, operational support, patient access, distribution, and trade and advocacy/policy work. To learn more about Coeus and the company’s offerings, visit www.coeusconsultinggroup.com .

Move Underscores Company’s Commitment to Provide Executive-Level Expertise to all Clients in every Engagement

April 8, 2020 – Devon, PA – Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has hired two executives to help grow and manage the company’s enhanced market access offerings. Kim Gwiadzdinski joins Coeus as the Vice President of Outcomes & Value Based Contracting and Dr. Neil Minkoff joins as Chief Medical Officer.

Gwiadzdinski brings more than 20 years of direct market access experience holding key strategic positions at large national payers including Prime Therapeutics and Cigna. In her previous roles, Kim was responsible for driving the strategy and implementing both traditional and value-based agreements designed to lower overall costs. Kim’s experience spans beyond the payer world as she has also worked for industry leading pharmaceutical companies Merck, AstraZeneca and NovoNordisk, leading their efforts in pricing and contracting, commercial innovation, affordability, and population health.

Dr. Minkoff brings more than 20 years of market access experience serving across a variety of roles in several companies. His previous employer experience includes serving as the Medical Director for Harvard Pilgrim Health Care, Associate Medical Director of Partners Community Healthcare, Co-Chair of Medical Management and of P&T for the CareGroup Network, Medical Director for Waltham Hospital and Commissioner of the Massachusetts Group Insurance Commission. In addition to his other work, Neil was Chief Medical Officer for a small company working on patient data where he helped develop the PRO Portal for capturing self-reported patient outcomes and clinical information to measure real-world experience.

“Coeus welcomes both Kim and Neil, two widely respected and highly regarded medical and pharmaceutical professionals, and we’re excited at the value and insights they will bring to our internal team and clients,” said Marc Hixson, CEO of Coeus. “They are a key reinforcing step in the company’s overall mission to bring executive-level consulting expertise to every client engagement. Our clients’ primary goal is to ensure that all appropriate patients have access to the most effective and innovative therapies available and Kim and Neil’s addition to Coeus considerably advances that cause.”

About Coeus Consulting Group
Founded in 2009, Coeus Consulting Group is a boutique life science market access consulting firm supporting pharmaceutical, biotech, medical device, and payors in the U.S. The company creates tailored, evidence-based solutions that drive business strategy and impacts their clients bottom lines. To learn more about Coeus and the company’s offerings, visit www.coeusconsultinggroup.com.

April 16, 2019 – Devon, PA – Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has launched a wholly-owned subsidiary – COEUS HEALTHCARE. Coeus Healthcare, the first value-based data aggregator and financial service company, offers pharmaceutical, biotech and gene therapy manufacturers the ability to offer a unified value-based care and financial reimbursement model to health plans and providers while offering patient mobility between insurers.

“Until now, there has been a significant unmet need -and an alarming lack of transparency- around pricing and value for life-saving therapies” said Harry Vargo, co-founder of Coeus Healthcare. “In today’s market, capability disparities, patient mobility and competitive inter-operability issues among insurers do not support the necessary longitudinal assessment of value for today’s innovative medicines, including gene and cell therapies.”

The health insurance community is looking to manufacturers to bring forward value-based models that can be supported across every payer, whether they operate in a commercial or government insured environment. Payers are also looking for payment solutions for these expensive, albeit often life-saving therapies. Coeus Healthcare was created to answer this need and offer manufacturers and insurers a third party, unbiased platform that provides confidence that key indicators of therapeutic effectiveness and the durability of that effectiveness are being uniformly monitored over an extended period of time. The addition of a unique payment model allows insurers to make or receive payments over time, regardless of the patient’s insurer.

About the Platform
Coeus Healthcare’s value-based adjudication platform is a cloud-based, blockchain supported collection and housing technology that allows disparate data sources to be combined and analyzed in order to better demonstrate total therapeutic impact on a patient’s illness. With today’s innovative and breakthrough medicines, there may not always be a clinical marker available to measure the value of the therapy. This platform offers a composite view of the therapeutic impact to both payers and manufacturers by incorporating metrics from claims data, electronic medical records, supply chain, patients and providers and wearables.

“Using Coeus Healthcare as an independent third-party platform, manufacturers are now able to collect meaningful information to support a therapy’s cost and a patient’s access to their medicines –regardless of the source of that information,” said Marc Hixson, co-founder of Coeus Healthcare and founder and CEO of Coeus Consulting Group.

Currently, the manufacturer, payer and regulatory bodies are looking towards value-based contracting as a means to validate therapeutic effectiveness and, as a result, prove or disprove the cost-benefit equation. Such one-off contracts can certainly support such an evaluation, however, it is a highly inefficient process and limits value-based contracts to those payers that can actually adjudicate these programs. Many smaller health plans, providers, and state Medicaid programs do not have the infrastructure to support such agreements. Coeus Healthcare offers an independent system that adjudicates, administers, and reconciles value-based agreements, but also enables proactive patient support that allows the healthcare system to intervene when needed.

“These agreements are larger than financial re-balancing for innovative medicines; these contracts enable us to assess therapeutic durability, support 21st century payment methodologies, and engage providers when proactive care is necessary,” stated Jim Clement, co-founder of Coeus Healthcare. “Ultimately, Coeus Healthcare offers patients and their families a dynamic, non-intrusive extension to the local delivery system while offering the manufacturer and payer a single platform to offer access to emerging therapeutics at a price point that can be justified.”

About Coeus Consulting Group
Founded in 2009, Coeus Consulting Group is a boutique life science strategy consulting firm supporting pharmaceutical, biotech, medical device, and payors in the U.S. The company creates tailored, evidence-based solutions that drive business strategy and impacts bottom lines. To learn more about Coeus and the company’s offerings, visit www.coeusconsultinggroup.com.

January 3, 2019 – Devon, PA – Coeus Consulting Group, a leading boutique life science consulting firm, today announced it has deepened its current offerings for the company’s pharma/biotech and payor clients in the areas of strategy, payor and PBM engagement, channel management and value-based pharmaceutical contracting.  Industry experts Jim Clement and Harry Vargo have joined the team to help build out and manage the company’s enhanced market access offerings.  

Both Clement and Vargo come to Coeus from Aetna, Inc. where they led the insurance provider’s efforts in establishing its value-based contracting initiative with pharmaceutical and biotech organizations.  Over the years, both have worked with dozens of manufacturers to expand access to emerging therapeutics while minimizing the financial impact of treatment failure.   


Drug pricing remains at the forefront of the debate around maintaining a sustainable healthcare system in the United States.  Patients and employers want continued access to innovative medicines while also being able to control the increasing costs in premiums and out-of-pocket expenses.  A value-based approach establishes clear, measured criteria that enables both manufacturers and insurers to only pay for medicines that show a sustained effect thereby limiting the financial exposure.            


“Jim and Harry are well-known in the industry for their innovative and unique approaches to payer strategies and contracting, and their type of vision is required in the ever-changing market we have today,” said Marc Hixson, CEO of Coeus. “As new disease modifying therapeutics and gene therapies come to market, the healthcare system will need to build and optimize new payment models to ensure patients have access to life-saving medicines while minimizing the overall financial burden. Utilizing Harry and Jim’s expertise, our clients who are both developing and paying for these therapies will be able to clearly measure success –demonstrating both the therapeutic benefit and the financial value of the medicine.”

Jim Clement, a former Aetna executive, most recently served as Executive Director, Value Based Care and Supply Chain Strategy where he focused largely on proving the value of pharmaceutical therapies. In that role, he was responsible for transforming the financing of the pharmacy benefit and leading Aetna’s enterprise relationships with pharmaceutical manufacturers.  Mr. Clement maintained administrative oversight for pharmacy benefit strategy, actuarial services, network administration, client pricing, analytics, and vendor management in addition to innovative contracting models that help drive value-based care.  He also served as a board member for sPCMA, collaborated with the Bipartisan Policy Center on innovative and value-based market access approaches for gene therapies, and served as an advisor to the Network for Excellence in Health Innovation (NEHI) on the publication of “Value-Based Contracting for Oncology Drugs.”

Prior to joining Coeus, Harry Vargo has served as a Director at Aetna for more than 14 years. As the Director of Value Based Contracting and Manufacturer Trade Relations, Vargo’s primary responsibility was to negotiate and execute rebate agreements with pharmaceutical manufacturers in support of their Commercial and Medicare drug formularies. In addition, Mr. Vargo focused on developing short- and long-term formulary strategies in concert with key market events to drive innovation at Aetna. 

About Coeus Consulting Group

Founded in 2009, Coeus Consulting Group is a boutique life science strategy consulting firm supporting pharmaceutical, biotech, medical device, and payors in the U.S. The company creates tailored, evidence-based solutions that drive business strategy and impacts bottom lines. To learn more about Coeus and the company’s offerings, visit www.coeusconsultinggroup.com.